MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • SciClone Pharmaceuticals, Inc. (SCLN) China Market Penetration Strategy Pays Off In Earnings 0 comments
    Oct 17, 2012 2:14 PM | about stocks: SCLN

    SciClone Pharmaceuticals is a U.S.-based specialty pharma company with 15 products currently in the market. The company's lead product, ZADAXIN® is approved in more than 30 countries for the treatment of hepatitis B, hepatitis C, as a vaccine adjuvant, and certain cancers.

    While SciClone's sales representatives fan throughout China, Asia, and Latin America, the company focuses primarily on China while seeking entrance into emerging markets through in-licensing agreements, similar to those currently held with Sanofi Aventis, Baxter, Pfizer, and Iroko.

    In the first quarter of 2012, SciClone received approval of Tramadol® to treat moderate-to-severe pain. On deck are plans to advance DC Bead, the company's next product lined up to potentially receiving approval.

    SciClone has topped its earnings estimates for the last four quarters, and in the second quarter of 2012 reported earnings of $0.20 per share, a penny increase over EPS of $0.19 the year prior.

    Revenues for the quarter came in at $40.3 million, an increase of 22% compared to revenues of $33.1 million for the second quarter of 2011, reflecting strength in sales of its ZADAXIN®, primary care and oncology business in China, and the inclusion of NovaMed Pharmaceuticals, which it acquired in April 2011.

    For more information visit www.sciclone.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: SCLN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.